心力衰竭治疗和HFpEF和HFrEF中高血压或不高血压的血清卡尼丁 - - 一项试点研究
Haruhito Harada1,2, Yasuhiro Nishiyama3,4, Atsushi Katoh3,5
1Department of Cardiology, Kurume University Medical Center, 155-1 Kokubu-machi, Kurume, Fukuoka, 839-0863, Japan. harada_haruhito@med.kurume-u.ac.jp.
概括
心力衰竭的治疗使得保留和减少排泄分数的患者中阿基卡尼丁/自由卡尼丁比率的升高正常化. 这表明心脏新陈代谢得到改善,特别是在高血压患者的HFpEF中.
科学领域:
- 心脏病学 心脏病学
- 代谢医学是一种代谢医学.
- 生物化学 生物化学
背景情况:
- 血清乙基卡尼丁与自由卡尼丁的比率 (AC/FC) 是心肌细胞脂肪酸β-氧化受损的生物标志物.
- 心力衰竭 (HF) 治疗对AC/FC水平的影响尚不清楚.
研究的目的:
- 研究标准医学治疗和心脏康复对HFpEF和HFrEF患者的AC/FC比率的影响.
- 探索AC/FC变化与心脏功能改善之间的关联.
主要方法:
- 对148名患有HFpEF和HFrEF的住院患者的回顾性分析.
- 在入院和出院时测量AC/FC比率和心声回声.
- 患者接受了标准的HF护理和心脏康复治疗.
主要成果:
- 与无症状对照人群相比,HFpEF和HFrEF患者在入院时的AC/FC比率显著更高.
- 处理导致了AC/FC比率的显著降低,达到与排放时的控制相当的水平.
- 在HFpEF中,AC/FC的减少与左心室喷射率的改善相关,特别是在高血压患者中,但不是在HFrEF中.
结论:
- 标准的HF治疗和心脏康复有效地使HFpEF和HFrEF的高AC/FC比率正常化.
- 在HFpEF中,AC/FC比率的正常化与心脏功能的改善有关,这表明它在治疗反应中发挥了作用.
- 需要进一步的大规模前性研究来证实这些发现并阐明潜在的机制.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
01:22Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
134
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
134
01:26Heart Failure Drugs: Inotropic Agents
511
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
511